Analysis of CMTM6 Expression in Patients With Acute Myeloid Leukemia

NCT05988047 | Completed

• 1 other identifier: CMTM6_AML
• Study Type: observational
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

In this study, we aim to investigate the expression of CKLF like MARVEL transmembrane domain containing 6 (CMTM6) in leukemia cells of patients with acute myeloid leukemia (AML). We will use peripheral blood samples and assess CMTM6 expression by flow cytometry and Western Blot.

Conditions

Acute Myeloid Leukemia, Adult

Outcome Measures

Primary Outcomes (2)

• CMTM6 expression (FC)

  CMTM6 expression on blasts/monocytes will be measured by flow cytometry

  At primary diagnosis

• T cell activation (FC)

  T cell activation and cytokine production will be measured by flow cytometry

  At primary diagnosis

Secondary Outcomes (1)

• CMTM6 expression (WB)

  At primary diagnosis

Study Arms (2)

Patients with AML

Peripheral blood will be taken at the timepoint of primary diagnosis and analyzed for CMTM6 expression and T cell activation

Healthy controls

Peripheral blood will be taken analyzed for CMTM6 expression and T cell activation

Eligibility Criteria

• Age: 18 Years - 99 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with AML at primary diagnosis ≥ 18 years of age or healthy probands ≥ 18 years of age

You may qualify if:

• age ≥ 18 years
• primary diagnosis of acute myeloid leukemia
• diagnosis results available
• written informed consent
• ability to understand the nature of the study and the study related procedures and to comply with them

You may not qualify if:

• age \< 18 years
• lack of informed consent

Sponsors & Collaborators

• University of Freiburg: lead

Study Sites (1)

Medical Center- University of Freiburg

Freiburg im Breisgau, CA, 79106, Germany

Location

MeSH Terms

Conditions

Leukemia, Myeloid, Acute

Condition Hierarchy (Ancestors)

Leukemia, Myeloid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: August 4, 2023
• First Posted: August 14, 2023
• Study Start: May 1, 2020
• Primary Completion: May 1, 2024
• Study Completion: May 1, 2024
• Last Updated: May 8, 2024

Record last verified: 2024-05

Data Sharing

• IPD Sharing: Will not share

Locations

DE (1)